Conviction
1 → 3
Conviction●●●○○3 of 5
Research target$205Snapshot target
Thesis statusINTACTLast reviewed 7/8/26
Market cap$21.60BSnapshot value
Research history
See all GH changes ↗What changed
Target
— → $205
Thesis status
NEEDS_MORE_DATA → INTACT
Last reviewed
Not reviewed → 7/8/26
Target
— → $205
Liquid biopsy pure-play: Guardant360/Guardant Reveal for oncology MRD and early detection. Recurring test-volume revenue model.
Colorectal cancer screening guideline inclusion (Shield blood test); MRD clinical adoption (Guardant Reveal); rising cancer burden driving testing volume.
Reimbursement risk (CMS coverage decisions); competitive pressure from Natera (Signatera) and Exact Sciences; binary regulatory outcomes on new test approvals.
needs X/Reddit sentiment sweep
Snapshot · 7/8/26🟢 Confirmed · 13F 17+/8- · short↓0.1
Snapshot · 7/8/26